MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...

MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abs ...

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

On the morning of2, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) ...

RemeGen’s Phase III trial of disitamab vedotin shows improved progression-free survival in advanced breast cancer patients ...

locally advanced or metastatic hepatocellular carcinoma: Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver, gall bladder, and bile ducts. The most common type of ...